Company Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.
The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.
It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development.
The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States.
It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
| Country | United States |
| Founded | 2002 |
| IPO Date | Oct 11, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 341 |
| CEO | Jerome B. Durso |
Contact Details
Address: 305 Madison Avenue Morristown, New Jersey 07960 | |
| Phone | 646-747-1000 |
| Website | interceptpharma.com |
Stock Details
| Ticker Symbol | ICPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001270073 |
| CUSIP Number | 45845P108 |
| ISIN Number | US45845P1084 |
| Employer ID | 22-3868459 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jerome B. Durso | President, Chief Executive Officer and Director |
| Andrew Saik | Chief Financial Officer |
| Rocco Venezia | Chief Accounting Officer and Treasurer |
| Jared M. Freedberg J.D. | General Counsel |
| Dr. M. Michelle Berrey M.D., M.P.H., MPH. | President of Research & Development and Chief Medical Officer |
| Nareg Sagherian | Executive Director of Global Investor Relations |
| David Ford | Chief Human Resources Officer |
| Dr. Mark Pruzanski M.D. | Founder, Advisor and Director |
| Linda M. Richardson | Executive Vice President and Chief Commercial Officer |
| Paul Nitschmann | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2023 | 8-K | Current Report |
| Nov 8, 2023 | POS AM | Post-Effective amendments for registration statement |
| Nov 8, 2023 | POS AM | Post-Effective amendments for registration statement |
| Nov 8, 2023 | POS AM | Post-Effective amendments for registration statement |
| Nov 8, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 8, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 8, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 8, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 8, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 8, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |